Note 9 - Related Party Transactions	6 Months Ended
Jun. 30, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 – RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements. One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no revenue or expenses generated by this partnership to date. On May 1, 2019, Mr. Gabriel executed a one -year contract with renewable three -month periods to continue as Chief Operating Officer for TumorGenesis. Mr. Gabriel will receive $13,500 in monthly cash payments. On May 21, 2019, the Company issued a third and restated common stock purchase warrant to Dr. Schwartz the Company’s CEO for value received in connection with the funding of all or a portion of the purchase price of his second amended and restated promissory note in the principal amount of $1,620,000. The Company issued an additional 34,518 warrants to Dr. Schwartz under the agreement in the second quarter, which reduced the value of the derivative liability by $32,215. As of June 30, 2019, the recorded derivative liability related to the agreement is $36,507. On May 9, 2019, Dr. Schwartz advanced $75,000 to the Company, on May 30, 2019, he advanced $200,000 to the Company, and on July 15, 2019 he advanced $25,000 to the Company. The loan earns 8% interest and is due on September 13, 2019, pursuant to the Amended and Restated Promissory Note. The loan is not connected to the previous note payable due to Dr. Schwartz and does not affect the warrant calculations regarding that notes interest.

NOTE

– RELATED PARTY TRANSACTIONS

The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company

may

be a party prior to their implementation, to assess whether such transactions meet applicable legal requirements.

One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been

revenue or expenses generated by this partnership to date.

May 1, 2019,

Mr. Gabriel executed a

one

-year contract with renewable

three

-month periods to continue as Chief Operating Officer for TumorGenesis. Mr. Gabriel will receive

$13,500

in monthly cash payments.

May 21, 2019,

the Company issued a

third

and restated common stock purchase warrant to Dr. Schwartz the Company’s CEO for value received in connection with the funding of all or a portion of the purchase price of his

second

amended and restated promissory note in the principal amount of

$1,620,000.

The Company issued an additional

34,518

warrants to Dr. Schwartz under the agreement in the

second

quarter, which reduced the value of the derivative liability by

$32,215.

As of

June 30, 2019,

the recorded derivative liability related to the agreement is

$36,507.

May 9, 2019,

Dr. Schwartz advanced

$75,000

to the Company, on

May 30, 2019,

he advanced

$200,000

to the Company, and on

July 15, 2019

he advanced

$25,000

to the Company. The loan earns

interest and is due on

September 13, 2019,

pursuant to the Amended and Restated Promissory Note. The loan is

not

connected to the previous note payable due to Dr. Schwartz and does

not

affect the warrant calculations regarding that notes interest.